Physician profile
Ruth Harrison
NPI 1245220524
$1,666.09
in general payments reported to CMS, 2019-2025
16 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $280 · 2023: $365 · 2024: $154 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.38 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $281.08 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $146.58 | 2025 | Dupixent |
| Janssen Biotech, INC. | $99.00 | 2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Sun Pharmaceutical Industries INC. | $89.17 | 2021 | |
| Revance Therapeutics, INC. | $77.11 | 2025 | Daxxify |
| Amgen INC. | $40.77 | 2021-2022 | |
| Genzyme Corporation | $32.73 | 2023-2025 | |
| Organon LLC | $32.66 | 2025 | |
| Dermavant Sciences, INC. | $24.49 | 2023 | Vtama |
| Ucb, INC. | $21.76 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $19.43 | 2025 | Nemluvio |
| Allergan, INC. | $15.33 | 2022 | |
| Lilly USA, LLC | $14.43 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.